Industry · AI News ·
Insilico Medicine advances AI drug for IPF to Phase III trials
Insilico Medicine is moving an AI-discovered drug for idiopathic pulmonary fibrosis into Phase III human trials. The study will test late-stage efficacy after earlier safety evaluations for a disease that causes lung scarring and progressive loss of respiratory function.